Last reviewed · How we verify

Treatment with PCSK9 inhibitors

Beijing Anzhen Hospital · Phase 3 active Small molecule

Treatment with PCSK9 inhibitors is a PCSK9 inhibitor Small molecule drug developed by Beijing Anzhen Hospital. It is currently in Phase 3 development for Hypercholesterolemia / elevated LDL cholesterol, Cardiovascular disease risk reduction in patients with elevated LDL-C. Also known as: Treatment with Proprotein convertase subtilisin/kexin type 9 inhibitors.

PCSK9 inhibitors block the PCSK9 protein, which normally degrades LDL receptors, thereby increasing LDL receptor availability on liver cells to remove more LDL cholesterol from the blood.

PCSK9 inhibitors block the PCSK9 protein, which normally degrades LDL receptors, thereby increasing LDL receptor availability on liver cells to remove more LDL cholesterol from the blood. Used for Hypercholesterolemia / elevated LDL cholesterol, Cardiovascular disease risk reduction in patients with elevated LDL-C.

At a glance

Generic nameTreatment with PCSK9 inhibitors
Also known asTreatment with Proprotein convertase subtilisin/kexin type 9 inhibitors
SponsorBeijing Anzhen Hospital
Drug classPCSK9 inhibitor
TargetPCSK9
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that binds to and promotes the degradation of LDL receptors on hepatocytes. By inhibiting PCSK9, these drugs prevent LDL receptor degradation, allowing more receptors to remain on the cell surface. This increases the uptake and clearance of LDL cholesterol from circulation, resulting in significant reductions in plasma LDL-C levels.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Treatment with PCSK9 inhibitors

What is Treatment with PCSK9 inhibitors?

Treatment with PCSK9 inhibitors is a PCSK9 inhibitor drug developed by Beijing Anzhen Hospital, indicated for Hypercholesterolemia / elevated LDL cholesterol, Cardiovascular disease risk reduction in patients with elevated LDL-C.

How does Treatment with PCSK9 inhibitors work?

PCSK9 inhibitors block the PCSK9 protein, which normally degrades LDL receptors, thereby increasing LDL receptor availability on liver cells to remove more LDL cholesterol from the blood.

What is Treatment with PCSK9 inhibitors used for?

Treatment with PCSK9 inhibitors is indicated for Hypercholesterolemia / elevated LDL cholesterol, Cardiovascular disease risk reduction in patients with elevated LDL-C.

Who makes Treatment with PCSK9 inhibitors?

Treatment with PCSK9 inhibitors is developed by Beijing Anzhen Hospital (see full Beijing Anzhen Hospital pipeline at /company/beijing-anzhen-hospital).

Is Treatment with PCSK9 inhibitors also known as anything else?

Treatment with PCSK9 inhibitors is also known as Treatment with Proprotein convertase subtilisin/kexin type 9 inhibitors.

What drug class is Treatment with PCSK9 inhibitors in?

Treatment with PCSK9 inhibitors belongs to the PCSK9 inhibitor class. See all PCSK9 inhibitor drugs at /class/pcsk9-inhibitor.

What development phase is Treatment with PCSK9 inhibitors in?

Treatment with PCSK9 inhibitors is in Phase 3.

What are the side effects of Treatment with PCSK9 inhibitors?

Common side effects of Treatment with PCSK9 inhibitors include Injection site reactions, Nasopharyngitis, Upper respiratory tract infection, Headache, Muscle pain.

What does Treatment with PCSK9 inhibitors target?

Treatment with PCSK9 inhibitors targets PCSK9 and is a PCSK9 inhibitor.

Related